Previous 10 | Next 10 |
2024-05-23 11:00:18 ET Joseph Pantginis from H.C. Wainwright issued a price target of $90.00 for CYTK on 2024-05-23 09:17:00. The adjusted price target was set to $90.00. At the time of the announcement, CYTK was trading at $48.71. The overall price target consensus is a...
2024-05-23 10:00:08 ET Serge Belanger from Needham issued a price target of $72.00 for CYTK on 2024-05-23 08:09:00. The adjusted price target was set to $72.00. At the time of the announcement, CYTK was trading at $59.23. The overall price target consensus is at $78.55 w...
2024-05-23 09:30:04 ET Needham analyst issues BUY recommendation for CYTK on May 23, 2024 08:09AM ET. The previous analyst recommendation was Buy. CYTK was trading at $59.23 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...
2024-05-23 07:15:08 ET Barclays analyst issues OVERWEIGHT recommendation for CYTK on May 23, 2024 05:37AM ET. The previous analyst recommendation was Overweight. CYTK was trading at $59.23 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-05-23 07:00:16 ET Akash Tewari from Jefferies issued a price target of $85.00 for CYTK on 2024-05-23 05:59:00. The adjusted price target was set to $85.00. At the time of the announcement, CYTK was trading at $59.23. The overall price target consensus is at $73.60 w...
2024-05-23 06:23:36 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics to get up to $575M in funding fro...
2024-05-22 17:10:41 ET Gainers: Chicken Soup for the Soul ( CSSEN ) +18% . Signature Bank ( OTC:SBNY ) +7% . PetMed Express ( PETS ) +6% . Prime Medicine ( PRME ) +6% . Sana Biotechnology ( SANA ) +5% . Losers: Cyto...
2024-05-22 17:08:12 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics CEO Blum says positioned to marke...
2024-05-22 16:15:13 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics CEO Blum says positioned to marke...
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced t...
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
Cytokinetics Incorporated Website:
2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...
2024-06-04 10:30:05 ET B. Riley analyst issues BUY recommendation for CYTK on June 4, 2024 08:58AM ET. The previous analyst recommendation was Buy. CYTK was trading at $49.018 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...